Page 63 - CIBEREHD2016-ENG

Most relevant scientific articles
• de Barrios O., Gyorffy B., Fernandez-Acenero M.J., Sanchez-Tillo E., Sanchez-Moral L., Siles L. et al. ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/ Mdm2/CtBP and repression of macroH2A1. Gut. 2016.
• Carballal S., Maisterra S., Lopez-Serrano A., Gimeno-Garcia A.Z., Vera M.I., Marin-Garbriel J.C. et al. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut. 2016.
• Quintero E., Carrillo M., Leoz M.-L., Cubiella J., Gargallo C., Lanas A. et al. Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study. PLoS Medicine. 2016;13(5).
• Vila-Navarro E., Vila-Casadesus M., Moreira L., Duran-Sanchon S., Sinha R., Gines A. et al. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts. Annals of Surgery. 2016.
• Dragani T.A., Castells A., Kulasingam V., Diamandis E.P., Earl H., Iams W.T. et al. Major milestones in translational oncology. BMC Medicine. 2016;14(1).
Hightlights
The research lines of our group are focused on characterizing those mechanisms involved in the development and progression of premalignant and malignant gastrointestinal and pancreatic lesions, in order to establish new diagnostic, therapeutic and preventive strategies. The main milestones achieved in the year 2016 are framed in the context of cooperative projects led by our group in the field of colorectal cancer (CRC) prevention, either screening or surveillance.
Regarding CRC surveillance, it is important to mention the initiation of the EPoS project, a multicenter, international, randomized controlled study aimed at establishing the best strategy for the surveillance
of patients who develop high- and low-risk adenomas, as well as serrated lesions. In addition, the risk stratification criteria proposed by the European Screening Guidelines have been reassessed.
With respect to CRC screening, we are continuing working in the context of the ColonPrev project, a prospective, randomized controlled study comparing fecal immunochemical testing and colonoscopy. After presenting the baseline results (N Engl J Med 2012, 366: 697-706), this year’s results have been focused on nested projects, including the identification of endoscopists’ characteristics influencing the quality
of colonoscopy, or the evaluation of electronic alert assistance in the Primary Care history to improve adherence to screening programs.
Finally, the development and validation of biomarkers of early cancer diagnosis, framed in the EPICOLON project, constitutes a strategic transversal action of several CIBEREHD groups. In this field, it is important to mention the aid granted by the Spanish Association against Cancer (1,200,000€) and the patent for a new diagnostic method in pancreatic cancer.
EHD
research Groups 63